Nitra vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $187M across Series A/B and facilities (Mar 2026). 740%+ revenue growth in 2025. $1B+ annualized processing volume. AI-native OS for 700+ clinics.
About
Nitra is an AI-native operating system for healthcare practices that consolidates payments, procurement, scheduling, and insurance verification into a single platform designed specifically for clinic operators. Founded in 2024, the company raised $187 million across Series A/B financing and credit facilities in March 2026, reporting 740%+ revenue growth in 2025 and surpassing $1 billion in annualized processing volume across 700+ clinic customers.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.